Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Climb Bio, Inc.'s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The filings cover operating and financial results, Regulation FD pipeline disclosures, material-event reports and capital-structure information for common stock listed under the symbol CLYM.
Company filings also describe budoprutug and CLYM116 development disclosures, financing arrangements, executive and accounting officer changes, and governance matters presented in proxy materials. Proxy disclosures address director elections, auditor ratification, charter amendments, equity incentive plan provisions, stockholder voting procedures and other annual meeting matters.
Climb Bio, Inc. entered an Open Market Sale Agreement with Jefferies LLC that allows it to sell shares of common stock with an aggregate offering price of up to $100.0 million through an at-the-market program under its existing Form S-3 shelf registration.
Sales, if made, will occur from time to time on the Nasdaq Global Market or otherwise at prevailing market prices, with Jefferies earning up to 3.0% of the gross sales price per share. Climb Bio also terminated its prior Equity Distribution Agreement with Oppenheimer, which had provided for up to $22.35 million of potential sales but resulted in no shares being sold before termination.
Climb Bio, Inc. entered into a Sales Agreement with Jefferies LLC to sell, from time to time, up to $100,000,000 of its common stock in an at‑the‑market offering on the Nasdaq Global Market under the symbol CLYM. The sales agent commission is up to 3.0% of gross sales. The prospectus supplement states the last reported sale price was $10.91 per share on June 11, 2026, and that there were 47,768,543 shares outstanding as of March 31, 2026. Net proceeds, if any, will be used for general corporate purposes, including working capital, R&D, clinical development, and potential acquisitions.
Climb Bio, Inc. reported that it has announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a clinical study of budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia. The study is designed to guide dose and regimen selection and to assess safety, platelet response and B-cell depletion in this patient group.
The company stated that it expects to release additional data from this trial by year-end 2026. It also included extensive cautionary language that these plans and expectations are forward-looking and subject to numerous risks, including clinical, regulatory, competitive and financing uncertainties related to budoprutug, CLYM116 and other product candidates.
Climb Bio, Inc. is registering the resale of up to 11,587,000 shares of its common stock for selling stockholders. This prospectus covers resale from time to time of 11,587,000 shares (9,481,000 outstanding shares and 2,106,000 shares issuable upon exercise of prefunded warrants) on behalf of the selling stockholders. The sales are resales by the selling stockholders; the company states it will not receive proceeds from resales, except that it will receive cash if the prefunded warrants are exercised for shares. The registration was filed to satisfy registration rights granted in connection with a private placement and includes a Beneficial Ownership Limitation of 33.0% that restricts exercise of the prefunded warrants. Shares outstanding were 57,263,023 as of May 14, 2026.
Climb Bio, Inc. reported a Form 4 showing a compensation-related stock option grant tied to RA Capital–associated entities. An option over 40,000 shares of Common Stock was awarded with an exercise price of $10.55 per share, expiring on June 4, 2036.
According to the footnotes, the option is held by Dr. Andrew Levin for the benefit of RA Capital Healthcare Fund and related Nexus funds and an account, and any net cash or stock from exercise will offset advisory fees owed to RA Capital Management, L.P. The reporting persons, including RA Capital entities and Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of any pecuniary interest. The option vests on the earlier of June 5, 2027 or the day immediately prior to the next annual stockholder meeting, subject to Dr. Levin’s continuous service.
Climb Bio, Inc. director Andrew David Levin was granted a stock option covering 40,000 shares of common stock at an exercise price of $10.55 per share. The option vests on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, contingent on continued service.
According to the disclosure, Levin holds this option for the benefit of RA Capital Healthcare Fund, related Nexus funds, and a separately managed account under an arrangement with RA Capital Management. Any net cash or stock from exercise must be turned over to the adviser to offset advisory fees, and Levin disclaims beneficial ownership of the option and underlying shares.
Climb Bio, Inc. director Kimberlee C. Drapkin received a grant of stock options covering 40,000 shares of Common Stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. Following this grant, she holds options on 40,000 shares directly. The options will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, subject to her continued service through that date.
Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. These options vest on the earlier of June 5, 2027 or immediately before the next annual meeting of stockholders, subject to his continued service. Following this grant, Williams holds 40,000 options directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Climb Bio, Inc. director Alexander Cumbo reported a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $10.55 per share, expire on June 4, 2036, and vest on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.